According to Sorrento Therapeutics 's latest financial reports the company's current revenue (TTM) is $64.27 M. In 2022 the company made a revenue of $62.84 M an increase over the years 2021 revenue that were of $52.9 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $64.27 M | 2.28% |
2022 | $62.84 M | 18.78% |
2021 | $52.9 M | 32.31% |
2020 | $39.98 M | 27.21% |
2019 | $31.43 M | 48.31% |
2018 | $21.19 M | -86.04% |
2017 | $0.15 B | 1762.81% |
2016 | $8.15 M | 77.6% |
2015 | $4.59 M | 20% |
2014 | $3.82 M | 732.07% |
2013 | $0.45 M | -21.25% |
2012 | $0.58 M | 10.32% |
2011 | $0.52 M | -22.47% |
2010 | $0.68 M | |
2009 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Karyopharm Therapeutics
KPTI | $0.14 B | 127.22% | ๐บ๐ธ USA |
Exelixis EXEL | $1.84 B | 2,773.26% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | $0.19 B | 200.06% | ๐บ๐ธ USA |